These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29442294)

  • 1. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.
    Pardridge WM; Boado RJ; Giugliani R; Schmidt M
    BioDrugs; 2018 Apr; 32(2):169-176. PubMed ID: 29442294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
    Giugliani R; Giugliani L; de Oliveira Poswar F; Donis KC; Corte AD; Schmidt M; Boado RJ; Nestrasil I; Nguyen C; Chen S; Pardridge WM
    Orphanet J Rare Dis; 2018 Jul; 13(1):110. PubMed ID: 29976218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein.
    Boado RJ; Pardridge WM
    Mol Pharm; 2017 Apr; 14(4):1271-1277. PubMed ID: 28279069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.
    Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Drug Metab Dispos; 2012 Oct; 40(10):2021-5. PubMed ID: 22822036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
    Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
    Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.
    Boado RJ; Hui EK; Lu JZ; Pardridge WM
    Bioconjug Chem; 2013 Jan; 24(1):97-104. PubMed ID: 23249376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys.
    Boado RJ; Hui EK; Lu JZ; Pardridge WM
    J Biotechnol; 2009 Oct; 144(2):135-41. PubMed ID: 19735678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
    Boado RJ; Ka-Wai Hui E; Zhiqiang Lu J; Pardridge WM
    Biotechnol Bioeng; 2014 Nov; 111(11):2317-25. PubMed ID: 24889100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin Receptor Antibody-α-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts.
    Boado RJ; Lu JZ; Hui EK; Lin H; Pardridge WM
    Mol Pharm; 2016 Apr; 13(4):1385-92. PubMed ID: 26910785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.
    Boado RJ; Hui EK; Lu JZ; Sumbria RK; Pardridge WM
    Bioconjug Chem; 2013 Oct; 24(10):1741-9. PubMed ID: 24059813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor.
    Boado RJ; Lu JZ; Hui EK; Sumbria RK; Pardridge WM
    Biotechnol Bioeng; 2013 May; 110(5):1456-65. PubMed ID: 23192358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-L-Iduronidase transport in neurites.
    Chen F; Vitry S; Hocquemiller M; Desmaris N; Ausseil J; Heard JM
    Mol Genet Metab; 2006 Apr; 87(4):349-58. PubMed ID: 16439176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
    Zhou QH; Boado RJ; Pardridge WM
    J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I.
    Martin PK; Stilhano RS; Samoto VY; Takiya CM; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; Marques FL; Otake AH; Chammas R; Han SW
    PLoS One; 2014; 9(3):e92420. PubMed ID: 24642723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.
    Lu JZ; Boado RJ; Hui EK; Zhou QH; Pardridge WM
    Biotechnol Bioeng; 2011 Aug; 108(8):1954-64. PubMed ID: 21351076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy in mucopolysaccharidosis type I.
    Miebach E
    Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.